Abstract：
Whether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random-effects meta-analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression-free survival (HR = 2.39, 95% CI 1.69-3.38), overall survival (HR = 2.40, 95% CI 1.94-2.98), disease-specific survival (HR = 2.57, 95% CI 1.71-3.88), and disease-free survival (HR = 2.67, 95% CI 1.51-4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.
摘要：
改良的格拉斯哥预后评分（mGPS）对头颈部鳞状细胞癌（HNSCC）患者是否有用仍存在争议。在EMBASE上进行电子数据库搜索，PubMed,从成立至2022年6月30日的Cochrane图书馆进行了研究选择和数据提取.使用随机效应荟萃分析评估mGPS与生存结果之间的关联，并表示为合并风险比（HR）和95％CIs。我们纳入了11项研究，涉及2017年HNSCC患者。较高的mGPS与较差的无进展生存期相关(HR=2.39,95%CI1.69-3.38),总生存率（HR=2.40，95%CI1.94-2.98），疾病特异性生存率（HR=2.57，95%CI1.71-3.88），HNSCC的无病生存率(HR=2.67，95%CI1.51-4.73，所有p≤0.001)。mGPS可以用作诊断为患有HNSCC的患者的有效预后生物标志物。
